ClinicalTrials.gg
CompletedNCT06690242Updated Jul 22, 2026

MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease

A Phase 2 interventional study of MT1013 and MT1013 in Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis, sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Shaanxi Micot Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Hyperparathyroidism, Secondary with a site in China — 4 open to participants now, 5 under way, 1 of them phase 3. Hyperparathyroidism, Secondary · China.

Enrollment
10th of 18
115 · median 158
Started
2024
with 4 others
Phase 2
5 of 23
1 open now
Registered
17th of 23
by date
Lead sponsor
4 of 23
Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Among the 23 studies in Hyperparathyroidism, Secondary with a site in China, this one is the 10th largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2024, is one of 5 in phase 2, and was the 17th registered.

Hyperparathyroidism, Secondary

188 studies on the registry are indexed under Hyperparathyroidism, Secondary; 15 are open to participants now.

Browse Hyperparathyroidism, Secondary studies →

Open to participants now

4 of the 23 studies in Hyperparathyroidism, Secondary with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Hyperparathyroidism, Secondary studies recruiting now, 5 (50%) set no upper age limit and 4 (40%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hyperparathyroidism, Secondary with a site in China, or all of them as a file.
02

Study summary

This is a randomized, positive controlled, and placebo-controlled phase II clinical study to evaluate the efficacy and safety of MT1013 injection in the treatment of chronic kidney disease with secondary hyperparathyroidism (SHPT) undergoing maintenance hemodialysis (MHD) subjects.

03

Conditions studied

  • Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Subject capable of understanding written information ,willing to participate in, and provide a written ;
  • 2.Male or female subjects must be at least 18 years old when signing the informed consent;
  • 3.The subjects must undergo regular maintenance hemodialysis three times a week for at least three months;
  • 4.Dialysate calcium concentration≥1.25 mmol/L (2.5 mEq/L);
  • 5.Diagnosed of Secondary Hyperparathyroidism (SHPT), with averaged iPTH ≥400 pg/ml14 days prior to screening;
  • 6.Receiving active vitamin D sterols must have had no more than a maximum dose change of 50% within the 1 month prior to screening, remain stable;
  • 7.Subject receiving calcium supplements, or phosphate binders must have had no more than a maximum dose change of 50% within the 2 weeks prior to screening, remain stable;

Exclusion criteria

Exclusion Criteria:

  • 1.The subjects underwent parathyroidectomy within 6 months prior to screening, or plan to undergo parathyroidectomy or ablation or radiation during the study;
  • 2.Gastrointestinal bleeding or peptic ulcer medical history within 6 months prior to screening;
  • 3.The of the subjects was less than 18kg/m2 or greater than 35 kg/m2;
  • 4.Subjects with severe uncontrolled hypertension, defined as systolic blood pressure>180 mmHg and/or diastolic blood pressure>110 mmHg(Except for transient blood pressure abnormalities seen during dialysis), despite optimal drug treatment prior to enrollment;
  • 5.History of epileptic seizures or ongoing epilepsy related treatment within 1 year prior to screening;
  • 6.Subjects with a history of malignant tumors within the past 5 years prior to screening;
  • 7.Subjects are allergic or intolerant to any component of the drug or Etelcalcetide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    MT1013 dose regimen 1

    MT1013 injection dose regimen 1 administered intravenously (IV) three times per week for 26 weeks.

    Drug: MT1013

  • Experimental
    MT1013 dose regimen 2

    MT1013 injection dose regimen 2 administered intravenously (IV) three times per week for 26 weeks.

    Drug: MT1013

  • Active comparator
    Etelcalcetide

    Etelcalcetide injection administered intravenously (IV) three times per week for 26 weeks.

    Drug: Etelcalcetide Hydrochloride

  • Placebo comparator
    Placebo

    Placebo administered intravenously (IV) three times per week for 26 weeks;

    Drug: Placebo

Interventions

  • DrugMT1013

    MT1013 is a novel calcimimetic agent

  • DrugMT1013

    MT1013 is a novel calcimimetic agent

  • the already-marketed therapeutic agents

  • DrugPlacebo

    The measure does not contain the active ingredients

06

What researchers measure

Primary outcomes

  1. Percentage of participants with > 30% reduction from baseline in mean iPTH during the efficacy assessment phase

    Time frame: Weeks 22 to 27, inclusive

Secondary outcomes

  1. Percentage of participants with > 50% reduction from baseline in mean iPTH during the efficacy assessment phase

    Time frame: Weeks 22 to 27, inclusive

07

Study locations

1 site
  • First Affiliated Hospital College of Medicine, Zhejiang University
    Hangzhou, Zhejiang 310003, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Aug 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2024
First posted
Nov 15, 2024
StartActual
Nov 4, 2024
Primary completionActual
Aug 30, 2025
CompletionActual
Aug 30, 2025
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06690242
Lead sponsor
Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 15, 2024
Start date
Nov 4, 2024
Primary completion
Aug 30, 2025
Completion
Aug 30, 2025
Last update
Jul 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MT1013

Start the discussion